New research sheds light on the significance of the glucocorticoid receptor in drug-resistant prostate cancer, showing that the development of drug resistance could be prevented by limiting the ...

An experimental drug for advanced prostate cancer has shown preliminary success in the first and second phases of clinical trials, shrinking tumors in the lab and reducing signs of the disease in ...

A new drug combination may benefit men whose prostate cancer has returned after primary surgery or radiation therapy. Pairing enzalutamide, an androgen receptor blocker, with the hormone therapy drug ...

New therapies are needed to help prevent the development of this condition. Researchers from the University of Iowa report that males taking three commonly prescribed prostate medications may lower ...

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in ...

Benign prostatic hyperplasia (BPH) and overactive bladder (OAB) syndrome are distinct health conditions but may cause similar symptoms, such as urgent or frequent urination. BPH is the noncancerous ...

Dutasteride treatment for benign prostatic hyperplasia (BPH) is associated with a significant increase in serum testosterone and a significant decrease in BMI among men with relatively lower baseline ...

Use of 5-α reductase inhibitors for benign prostatic hyperplasia (BPH) does not significantly increase the risk of hip fracture, researchers concluded in The Journal of the American Medical ...